title: Thioridazine: the good and the bad.
abstract: Thioridazine is a phenothiazine drug which has previously been extensively used for its antipsychotic properties as it is associated with a low risk of extra-pyramidal side-effects. There is good evidence to suggest that, in common with other phenothiazine drugs, thioridazine has important anti-microbial activity and is a potential candidate for development as an anti-microbial drug against multi-resistant organisms, including drug-resistant strains of M. tuberculosis. The clinical pharmacology and toxicity profile of thioridazine are reviewed in this article and the implications for future drug development along with the patent are discussed.
authors.affiliation: Consultant Physician and Clinical Pharmacologist, Wolfson Unit of Clinical Pharmacology, Newcastle University, UK. ruben.thanacoody@ncl.ac.uk
authors.forename: R H
authors.initials: RH
authors.lastname: Thanacoody
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D055808:Drug Discovery; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000472:pathogenicity; D010330:Patents as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013881:Thioridazine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000995:Antitubercular Agents; D013881:Thioridazine